118 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
nsu7sj7v
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
6vrww6mw
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
1mcsfh pmmre10
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
m5u7kq7i
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-10.1
r1h9j2ybzqa
6 Mar 23
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
6:47am
425
EX-10.1
rswom 6wmzfzdm1y
6 Mar 23
Business combination disclosure
6:36am
425
EX-10.2
46wb519r p07
6 Mar 23
Business combination disclosure
6:36am
8-K
EX-10.1
c8652m6sctyux5n0
6 Mar 23
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
6:34am
8-K
EX-10.2
c3f0qkso2jw97eny168u
6 Mar 23
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
6:34am
8-K
EX-10.1
5hsmoszbfs1sqv
16 Feb 23
Adaptimmune Announces Changes to Board of Directors
8:14am
8-K
EX-10.1
e05jjb k9
20 Dec 22
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-10.1
v47y7 rb0n4pgt
15 Jun 22
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-10.2
zbi3ewypdt1 u7cr7x
15 Jun 22
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-10.1
9lr42 yzp
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.01
7x93lwo9 ihzgwtrg393
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am